Оптимизация ведения пациентов с фибрилляцией предсердий
Диссертация
Даже в высокоразвитых странах затраты на здравоохранение ограничены. И наиболее эффективно направлять эти ресурсы на развитие методов профилактики, диагностики и лечения, практическая польза которых подтверждена рандомизированными исследованиями и научно обоснована. Технологические карты служат инструментом для создания и реализации программ медицинской помощи, основанных на данных клинических… Читать ещё >
Список литературы
- Аксаментов М.Г. Медико-экономические стандарты: взгляд со стороны врача амбулаторного приема //Здравоохранение. 1998. — № 12. — С.19−21.
- Актуальные вопросы кардиологии: Курс лекций. 4.1 //Под ред. Д. Г. Иоселиани. М.: Изд. дом «ЛеТим». — 343 с.
- Бащинский С.Е. Evidence-Based Medicine и Международный журнал медицинской практики. О необходимости научно-обоснованной медицинской практики //Междунар. журн. мед. практики. 1996. — № 1. — С.6−11.
- Бокерия Л., Ревишвили А., Ольшанский М. Хирургическое лечение фибрилляции предсердий: история вопроса и перспективы //Progress in biomedical research. 1997. — № 2. — C.74−83.
- Быкова E.C., Голицын С. П., Атьков О. Ю. Возможности и роль чреспищеводной эхокардиографии в решении вопросов лечения больных с мерцательной аритмией //Терапевт, арх. 2001. — № 8. — С.77−80.
- Вардосапидзе СЛ., Восканян Ю. Э. Безопасность пациента как интегральный критерий качества стационарной медицинской помощи //Проблемы управления здравоохранением. 2003. — № 1. — С. 18−20.
- Воробьев П., Авксентьева М. Что как оценивать? Роль стандартизации в государственной программе управления качеством в здравоохранении //Рос. врачеб. газ. Мед. вестн. 2002. — № 31 (230).
- Воробьев П.А., Аксюк З. Н. Стандартизация и оценка качества медицинской помощи //Проблемы стандартизации здравоохранения. 1999. -№ 1. — С.15.
- Вялков А.И. Управление качеством в здравоохранении //Проблемы управления здравоохранением. 2003. -№ 1. — С.5−12.
- Гейтс Б. Бизнес со скоростью мысли. М.: Эксмо-Пресс, 2000. — 477 с.
- Гличев A.B. Основы управления качеством продукции. 2-е изд., перераб. и доп. -М.: Стандарты и качество. — 2001. — 424 с.
- Глоссарий: Качество мед. помощи /Рос.-амер. межправительств, комис. по эконом, и технолог, сотрудничеству, Ком. по здравоохранению Россия-США. М., 1999.-61 с.
- Гуков А. О, Жданов A.M. Возможности постоянной кардиостимуляции в профилактике фибрилляции и трепетания предсердий //Вестн. аритмологии. 2000. -№ 16. — С.78−84.
- Деминг В.Э. Выход из кризиса. Тверь: Альба, 1994. — 243 с.
- Де Фритас Г. Р., Богусславский Дж. Первичная профилактика инсульта //Инсульт. 2001. — № 1. — С.7−31.
- Дзейл Д. Инициатива качества: анализ имеющихся заделов //Серия «Все о качестве. Зарубежный опыт». -М.: Терек, 2002. Вып. 31. — С.22−32.
- Дьяченко В.Г. Экспертиза качества медицинской помощи: (Вопр. теории и практики): Программа ЗдравРеформ. М., 1996. — 203 с.
- Жулинский С.Ф., Новиков Е. С., Поспелов В. Я. Статистические методы в современном менеджменте качества. М.: Фонд «Новое тысячелетие», 2001. — 208 с.
- Индейкин E.H. Клинический аудит: опыт Великобритании //Качество мед. помощи. 2002. — № 2. — С.45−53.
- Канорский С.Г., Скибицкий В. В., Федоров A.B. Клиническая эффективность и возможный риск противорецидивной терапии пароксизмальной фибрилляции предсердий: необходимость учета вегетативных влияний на сердце //Вестн. аритмологии. 1997. — № 7. — С.20−26.
- Колыхалова Г. А. Модель Европейского фонда по управлению качеством //Проблемы управления здравоохранением. 2003. — № 1. — С.32−34.
- Кондо И. Управление качеством в масштабах компании. Н. Новгород: Приоритет, 2002. — С. 19.
- Косов В.А., Простак Л. Г. Профилактика сердечно-сосудистых заболеваний и ее экономические аспекты у оперированных больных ишемической болезнью сердца на этапах реабилитации //Мед. помощь. 2000. — № 1. — С.6−7.
- Кутарски А., Полещак К., Олежчак К. и др. Биатриальная стимуляция: клинический опыт применения у 264 пациентов //Progress in biomedical research.1998. -№ 3. С. 113−121.
- Ланг Ф., Биберле Т., Данилович Д. Предупреждение предсердной тахиаритмии посредством кардиостимуляции //Progress in biomedical research.1999.-№ 4.-С. 122−131.
- Леонтьев С.Л., Беллавин В. А., Боярский А. П. О значении стандартов для медико-страховой экспертизы в системе обязательного медицинского страхования //Гл. врач. 1996. — № 4. — С.71−73.
- Лисицын Ю.П. Общественное здоровье и здравоохранение. М.: ГЭОТАР-МЕД, 2002.-517 с.
- Лицензирование, стандартизация /М-во здравоохранения РФ //www.minzdrav-rf.ru//documents/20 030 318/part07.htm.
- Мазур H.A. Фибрилляция предсердий //Клин, фармакология и терапия. -2003. Т.12., № 3. — С.32−35.
- Малков Л.П. Тенденции развития здравоохранения в США //Компьютер, технологии в медицине. 1998. -№ 2. — С. 14−16.
- Мараш С.А. «Шесть сигм» философия качества в новом тысячелетии //"Шесть сигм" как инструмент управления. Серия «Все о качестве. Зарубежный опыт». — М.: Терек, 2001. — Вып. 26. — 32 с.
- Международные стандарты. Сборник новых версий стандартов ИСО серии 9000. М.: Изд-во ВНИИС Госстандарта России, 1995.
- Минздрав РФ в поисках российской концепции качества в здравоохранении. А может быть не стоит изобретать велосипед?: (Ред. материал) //Качество мед. помощи. 2002. — № 4. — С.46−48.
- Московские городские стандарты стационарной медицинской помощи для взрослого населения. М., 1997. — 383 с.
- Мыльникова И.С. Создание гарантий качества в медицине и здравоохранении //Качество мед. помощи. 1996. — № 1. — С.34−40.
- Назаренко Г. И., Михеев А. Е. Больничные информационные системы. Разработка. Внедрение. Эксплуатация: Учеб.-метод. пособие. М.: Медицина XXI, 2003.-320 с.
- Назаренко Г. И., Осипов Г. С. Медицинские информационные системы и искусственный интеллект. М.: Медицина XXI, 2003. — 240 с.
- Назаренко Г .И., Полубенцева Е. И. Смена парадигмы управления больницей как альтернатива «двойным» стандартам медицинской помощи //Проблемы управления здравоохранением. 2003. — № 2. — С.25−36.
- Назаренко Г. И., Полубенцева Е. И. Управление качеством медицинской помощи. М.: Медицина, 2000. — 367 с.
- Назаренко Г. И., Полубенцева Е. И., Черкашов A.M. Клинические руководства инструмент обеспечения качества медицинской помощи пациентам с болью в пояснице //Вестн. травматологии и ортопедии им. H.H. Приорова. — 2002. -№.1. — С.89−91.
- Научно-организационные подходы к повышению качества медицинской помощи населению /М-во здравоохранения РФ // www. minzdrav-rf.ru//documents/ 20 030 318/ part14. htm
- Обри Ч. Прорыв к уровню обслуживания мирового класса с использованием методологии «шесть сигм» //"Шесть сигм" как инструмент управления. Серия «Все о качестве. Зарубежный опыт». М.: Терек, 2001. — Вып. 26. — 32 с.
- Огвоздин В.Ю. Управление качеством: Основы теории и практики. М.: Дело и сервис, 1999. — 160 с.
- Окрепилов В.В. Управление качеством: Учеб. для вузов. 2-е изд., перераб. и доп. — М.: Экономика, 1998. — 639 с.
- Оценка качества и эффективности медицинской помощи /Под ред. О. П. Щепина. М.: НИИ соц. гигиены, экономики и управления здравоохранением им. Н. А. Семашко, 1995. — 80 с.
- Панченко Е.П. Профилактика кардиоэмболического инсульта у больных мерцательной аритмией //Кардиоваскуляр. терапия и профилактика. 2003. — Т.2, № 3. — С.64−69.
- Панченко Е.П., Кропачева Е. С., Жаркова Т. В. Роль антитромботической терапии у больных мерцательной аритмией (к выходу международных рекомендаций) //Сердце. 2002. — Т.1, № 2. — С.88−91.
- Парфенов В.А. Лечение инсульта //РМЖ. 2000. — Т.8, № 10. — С.426−432.
- Приказ МЗ РФ № 277 от 23.02.92 г. «О создании системы медицинских стандартов (нормативов) по оказанию медицинской помощи населению РФ».
- Приказ МЗ РФ № 134 от 08.04.96 г. «О временных отраслевых стандартах объема медицинской помощи».
- Приказ МЗ РФ № 363/77 от 24.10.96 г. «О совершенствовании контроля качества медицинской помощи населению Российской Федерации».
- Приказ МЗ РФ от 09.10.98 № 300 «Об утверждении стандартов (моделей протоколов) диагностики и лечения больных с неспецифическими заболеваниями легких».
- Приказ МЗ РФ от 03.07.99 № 303 «О введении в действие отраслевого стандарта «Протоколы исследования больных. Общие требования».
- Проект. Отраслевая целевая программма «Управление качеством в здравоохранении на 2003−2007 годы'7/Проблемы управления здравоохранением. -2003. -№ 1. С.81−86.
- Проектирование медицинских технологических процессов (подготовка технологической карты ведения больного): Учеб.-метод. пособие /Мед. центр Банка России /Под ред. Г. И. Назаренко, Е. И. Полубенцевой. М., 2001. — 29 с.
- Розова H.K. Управление качеством: Учеб. пособие. СПб.: Питер, 2002. -223 с.
- Сабанов В.И., Ивашова В. В. Концептуальные подходы к проблеме обеспечения качества медицинской помощи //Гл. врач. 1997. — № 1. — С.23−28.
- Саггези Х.Д. Всеобъемлющие системы управления почему и как?//Изменения в системах управления в 21-ом веке. Серия «Все о качестве. Зарубежный опыт». — М.: Терек, 2001. — Вып. 28. — 29 с.
- Сердечная недостаточность и аритмии. 4.2. Фибрилляция предсердий. Ред. Статья //Клин, фармакология и терапия. 2003. — Т.12., № 4. — С.9−12.
- Социальная гигиена (медицина) и организация здравоохранения //Под ред. Ю. П. Лисицына. Казань, 1998. — 697 с.
- Сыркин A.JI., Добровольский A.B. Тактика лечения больных с постоянной формой мерцательной аритмии: современное состояние проблемы //Consilium Medicum. -2003. -Т.З, № 10. С.492−96.
- Тиллингаст С.Дж. Россия выбирает жизнь: программа реформирования российского здравоохранения. 4.1 //Междунар. журн. мед. практики. 1997. — № 3. -С.54−62.
- Тиллингаст С.Дж. Россия выбирает жизнь: программа реформирования российского здравоохранения. Ч. 2 //Междунар. журн. мед. практики. 1997. — № 4. — С.56−64.
- Тихомирова О.В., Маматова Н. Т., Клочева Е. Г., Сорокоумов В. А. Особенности течения ишемического инсульта у пациентов с кардиогенными источниками эмболии //Инсульт. 2002. — № 2. — С.31−34.
- Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология: Основы доказат. медицины. М.: Медиа Сфера, 1998. — 347с.
- Фомина И.Г., Ветлужский А. В. Существует ли оптимальная стратегия лечения рецидивирующей мерцательной аритмии //Кардиоваскуляр. терапия и профилактика. -2003. Т.2, № 3. — С.70−79.
- Чирейкин JI.B., Татарский Б. А. Тактика ведения больных с фибрилляцией предсердий //Вестн. аритмологии 1999. — № 12. — С.5−19.
- Штейнгард Ю.Н., Сергеева В. П., Волкова Л. И., Индель Т. Н. Избыточное обследование и фармокотерапия это достоинство или недостаток //Терапевт, арх. — 1984. — № 1. — С.52−55.
- Щепин О.П., Линденбратен А. Л., Зволинская P.M., Голодненко В. Н. От оценки качества медицинской помощи к его обеспечению //Бюл. НИИ соц. гигиены, экономики и упр. здравоохранением им. Н. А. Семашко. 1997. — Вып. 4. -С.10−14.
- Эльштейн Н.В. Диагностические ошибки интернистов: Общ. Аспекты //РМЖ, — 1998.-Т.4,№ 1.-С.1−9.
- Эталонное тестирование (бенчмаркинг) //Серия «Все о качестве. Зарубежный опыт» /Под ред. Герасимова Г. Е. М.: Терек. 2002. — Вып. 32. — 43 с.
- HIMSS: Данные опроса «Перспективы развития информационных технологий в здравоохранении» //Компьютер, технологии в медицине. 1998. -№ 2. -С.63−65.
- Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomized clinical trial //Lancet. 1996. — Vol.348. — P.633−638.
- Agency for Healthcare Reseach and Quality. Management of new onset atrial fibrillation: Evidence report/technology number 12. Rockville (Md.): AHRQ, 2001. -P.173−191.
- Aime-Sempe C., Folliguet T., Rucker-Matrin C. et al. Myocardial cell death in fibrillating and dilated human right atrium //J. Amer. Coll. Cardiol. 1999. — Vol.34. -P.1577−1586.
- Albers G.W., Dalen J., Laupacis A. et al. Antithrombotic therapy in atrial fibrillation //Chest. 2001. — Vol.119. — P.194S-206S.
- Albers G.W., Yim J.M., Belew K.M. et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals //Arch. Intern. Med. 1996. -Vol.156.-P.2311−2316.
- Alexander C., Flaker G.C. Practical management of atrial fibrillation //South Med. J. 1999. — Vol.92, N12. — P. l 136−1143.
- Allessie M. Electrical remodeling and chronic atrial fibrillation //Symposium atrial fibrillation in Asturias: The electrophysiology of atrial fibrillation, Oviedo (Asturias, Spain), June 9−11, 2000: Presentations and abstracts. P. 15.
- Allessie M.A., Boyden P.A., Camm A.J. et al. Pathophysiology and prevention of atrial fibrillation //Circulation. 2001. — Vol.103. -P.769−777.
- Al-Saady N.M., Sopher M. Prothrombotic markers in atrial fibrillation: what is new? ////Eur. Heart J. 2001. — Vol.22. — P.1635−1639.
- Ammer R. Pain threshold for low energy intracardiac cardioversion of atrial fibrillation with low or no sedation //PACE. 1997. — Vol.20. — P.230−236.
- Ammer R., Aretz T., Keane D., Ruskin J. Induction of apoptosis in atrial and Bcl-2 upregulation in ventricular myocytes is a transient persistent atrial fibrillation // Europ. Heart J. 2002. — Vol.4. — P. 281.
- Ansell J., Hirsh J., Dalen J. et al. Managing oral anticoagulant therapy //Chest. -2001. Vol.119.-P.22S-38S.
- Antiarrhythmics: The Drug Classification System //NASPE Milestones in the evolution of the study of arrhythmias. -www.medscape.com/Medscape/CNO/2001/NASPEMilestones/ public.
- Antonette Diaz L., Clifton G.D. Dofetilide: A new class III antiarrhythmic for the management of atrial fibrillation //Prog. Cardiovasc. Nurs. 2001. — Vol.16, N.3. -P.126−129.
- Arnold A. Z, Mick M. J, Mazurek R.P. et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter //J. Amer. Coll. Cardiol. 1992.-Vol.19.-P.851−855.
- Atral Fibrillation Follow-up Investigations of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation //New Engl. J Med. 2002. — Vol.347, N23. — P.1825−1833.
- Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials //Arch. Intern. Med. 1994. — Vol.154. — P.1449−1457.
- Bagian J.P., Gosbee J., Lee C.Z. et al. The Veterans affairs root cause analysis system in action //The Joint Commiss. J. Quality Improv. 2002. — Vol.28, N10. -P.531−545.
- Baker D.W., Hayes R.P., Massie B.M., Craig C.A. Variations in family physicians and cardiologists care for patients with heart failure //Amer. Heart J. 1999. — Vol.138, N5. -P.826−834.
- Barclay L. ACP/AAFP issue guidelines for management of atrial fibrillation // Ann. Intern. Med. 2003. — Vol.139. — P.1009 — 1017.
- Barnett O. Computers in medicine //J. Amer. Med. Assoc. 1990. — Vol.263, N19.-P.2631−2633.
- Bates D.W., Cullen D.J., Laird N. et al. Incidence of adverse drug events and potential adverse drug events: Implication and prevention //J. Amer. Med. Assoc. 1995. -Vol. 274, N1.-P.29−34.
- Becher E.C., Chassin M.R. Improving the quality of health care: Who will lead? //Health Aff. 2001. — Vol.20, N5. — P. 164−179.
- Bella P.D., Brugada P., Talajic M. et al. Atrial fibrillation in patients with accessory pathways: importance of the conduction properties of the accessory pathway //J. Amer. Coll. Cardiol. 1991.-Vol.17.-P. 13 52−13 56.
- Bellandi F., Cantini F., Tiziana P. et al. Effectiveness of intravenous propafenone of recent-onset atrial fibrillation: A placebo-controlled study //Clin.Cardiol. 1995. -Vol.18.-P.631−634.
- Bellandi F., Dabizzi R., Niccoli L. et al. Propafenone and Sotalol: Long term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation: A placebo-controlled double-blind study IIJ. Ital. Cardiol. 1996. — Vol.26. — P.379−390.
- Beller G. Presidental address: Quality of cardiovascular care in the U.S. //J. Amer. Coll. Cardiol. 2001. — Vol.38, N3. — P.587−594.
- Benjamin E.J., Wolf P.A., D’Agostino R.B. et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study //Circulation. 1998. — Vol.98, N10. -P.946−952.
- Bernstein S.J., Hilborne L.H. Clinical indicators: the road to quality care? //Jt. Comm. J. Qual. Improv. 1993. — Vol.19, N11.- P.501−509.
- Berry C., Stewart S., Payne E., et al. Electrical cardioversion for atrial fibrillation: outcomes in «real-life» clinical practice // Int. J. Cardiol. 2001. — Vol.81. — P.29−35.
- Berwick D., Nolan T. Physicians as leaders in improving health care //Ann. Intern. Med. 1998. — Vol.128. — P.289−292.
- Bhandari A. Modern trends in the management of atrial fibrillation //Cardiovasc. Rev. Rep. 2003. — Vol.24, N.7. — P.357−365.
- Bianconi L., Boccadamo R., Pappalardo A. et al. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of resent onset //Amer. J Cardiol. 1989. — Vol.64. — P.335−338.
- Bjerkelund C.J., Orning O. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation //Amer. J. Cardiol. -1969.-Vol.23.-P.208−216.
- Black I.W., Chesterman C.N., Hopkins A.P. et al. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation //J. Amer. Coll. Cardiol. 1993. — Vol.21. -P.451−457.
- Black I.W., Fatkin D., Sagar K.B. et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: a multicenter study //Circulation. 1994. — Vol.89. -P.2509−2513.
- Blackshear J.L., Johnson W.D., Odell J.A. et al. Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation //J. Amer. Coll. Cardiol. 2003. — Vol.42, N7. — P. 1249−1252.
- Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators //Arch. Intern. Med. 1996. -Vol.156.-P.409−416.
- Blitzer M., Costeas C., Kassotis J. et al. Rhythm management in atrial fibrillation with a primary emphasis on pharmacological therapy: Pt.l. //PACE. — 1998. — Vol.21. -P.590−602.
- Board N., Brennan N., Caplan G. Use of pathology services in re-engineered clinical Pathways //J. Qual. Clin. Practice. 2000. -Vol.20. -P.24−29.
- Boissel J.P., Wolf E., Gillet J. et al. Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation //Eur. Heart J.-1981.-Vol.2.-P.49−55.
- Boone J., Connohy S. Follow-up of atriall fibrillation: The initial experience of the Canadian Registry of Atriall Fibrillation //Eur. Heart J. 1996. — Vol.17. — P.48−51.
- Boos C., Thomas M., Jones A., More R. Higher energy cardioversion for atrial fibrillation: the way forward //Abstracts of the XXIII Congress of the European Society of Cardiology, Sept., 2001, Stockholm, Abs.169.
- Borgeat A., Goy J.J., Maendly R. et al. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm //Amer. J Cardiol. 1986. — Vol.58. — P.496−498.
- Boriani G., Biffi M., Cappucci A. et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial //Ann. Intern. Med. 1997. — Vol.126. — P.621−625.
- Bosch R.F., Zeng X., Grammar J.B. et al. Ionic mechanisms of electrical remodeling in human atrial fibrillation//Cardiovasc. Res. 1999. — Vol.44. -P.121−131.
- Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation //N. Engl. J. Med. 1990. — Vol.323. — P.1505−1511.
- Botto G., Bonini W., Broffoni T. et al. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: Is in-hospital admission absolutely necessary? //PACE. 1996. — Vol.19. — P. 1939−1943.
- Botto G. L, Luzi M., Sagone A. Atrial fibrillation: the remodelling phenomenon //Eur. Heart J. 2003. — Vol.5, Suppl.H. — P.1H-7H.
- Botto G. L, Belotti G., Ciro A. et al. Verapamil in prevention early recurrences of atrial fibrillation. Final results of the VERAF study //Eur. Heart J. 2002. — Vol.4, Abstr. suppl. — P.660.
- Braunwald E., Antman E.M. Evidence based coronary care //Ann. Intern. Med. -1997. -Vol.126. P.551−553.
- Brennan T.A.,. Leape L.L., Laird N.M. et al. Incidence of adverse events and negligence in hospitalized patients: Results of the Harvard medical practic study //New Engl. J. Med. 1991. — Vol.324, N6. — P.370−376.
- Brignole M., Gammage M., Jordaens L., Sutton R. Report of a study group on ablate and pace therapy for paroxysmal atrial fibrillation. Barcelona Discussion Group on Arrhythmias of the European Society of Cardiology //Europace. 1999. — Vol.1. — P.8−13.
- Bril A. Recent advances in arrhythmia therapy: treatment and prevention of atrial fibrillation //Curr. Opin. Pharmacol. 2002. — Vol.2, N2. — P. 154−159.
- Brown A. Atrial fibrillation //Quality of care for cardiovascular conditions: A review of the literature and quality indicators /Ed. by Kerr E.A. et al.- Rockville (Md.): AHRQ, 2000. -P.49−67.
- Brugada R., Tapscott T., Czernuszewicz G.Z. et al. Identification of a genetic locus for familial atrial fibrillation //New Engl. J. Med. 1997. — Vol.336, N13. — P.905−911.
- Bussey E. Medical errors in US hospitals usually result from systems failure //Medscape. Reuters Medical News. 2000.06.22.
- Byrne-Quinn E., Wing A.J. Maintenance of sinus rhythm after DC reversion of atrial fibrillation. A double-blind controlled trial of long-acting quinidine bisulfate //Br. Heart J. 1970. — Vol.32. — P.370−376
- Cain M.E. Atrial fibrillation rhythm or rate control //New Engl. J. Med. — 2002. — Vol.347, N23 — P. 1822−1823.
- Cairns J.A. Atrial fibrillation: antithrombotic therapy //Evidence based cardiology /Eds. Yusuf S. et al. London: BMJ Books, 1998. -P.544−552.
- Cameron A., Scharwartz M. Prevalence and significance of atrial fibrillation in coronary disease (CASS Registry) //Amer. J. Cardiol. 1988. — Vol.61. — P.714−717.
- Camm AJ. Future role of electrical therapy for atrial fibrillation: reality for all //Eur. Heart J. 2001. — Vol.3, Suppl. P. — P. 53P -56P.
- Camm A.J. Safety of antiarrhythmic agents: The final frontier in treating atrial fibrillation? //www.medscape.com/Medscape/cardiology/Treatment Update/2000/ tu03.
- Campbell H., Hotchkiss R., Bradshaw N., Porteous M. Integrated care pathways //Br. Med. J. 1998. — Vol.318, N10. — P.133−137.
- Campbell T., Gavaghan T., Morgan J. Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomized trial //Br. Heart. J. 1985. — Vol.54. — P.86−90.
- Cannon C., CTGara P. Critical pathways for acute coronary syndromes. What are critical pathways? //www.chestpainonline.org/30.10.2000.
- Cannon C., Hand M., Bahr R. et al. Critical pathway for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program //Amer. Heart J. 2002. — Vol.143. — P.777−789.
- Capucci A., Aschieri D. Antiarrhythmic drug therapy: what is certain and whatis to come //Eur. Heart J. 2003. — Vol.5, Suppl. H. — P.8H -18H.
- Capucci A., Boriani G., Botto G. et al. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide //Amer. J. Cardiol. 1994. — Vol.74. — P.503−505.
- Capucci A., Boriani G., Rubino I. et al. A controlled study on oral propafenone versus digoxin plus quinidine in conversion recent onset atrial fibrillation to sinus rhythm //Int. J. Cardiol. 1994. — Vol.43. -P.305−313.
- Capucci A., Lenzi T., Boriani G. et al. Efficacy of propafenone toconvert atrial fibrillation to sinus rhythm: a controlled study comparing acute intravenous infusion vs oral dosing. // Circulation. 1993. — Vol.88. — P.441−445.
- Capucci A., Lenzi T., Boriani G. et al. Pharmacologic conversion of paroxysmal atrial fibrillation: A single placebo controlled study on oral flecainide and intravenous amiodarone //Cardiovasc. Drug Ther. 1991. — Vol.5, Suppl. 3. — P. 359.
- Capucci A., Villani G., Marrazzo N., Piepoli M. The complementary role of drug, ablation and device in the electrical therapy of atrial fibrillation //Eur. Heart J. 2001. -Vol.3, Suppl. P. -P.47P -52P.
- Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction //New Eng. J Med. 1989 — Vol.321. — P.406−412.
- Cardioembolic stroke, early anticoagulation, and brain hemorrhage. Cerebral Embolism Study Group //Arch. Intern. Med. 1987. — Vol.147. -P.636−640.
- Carlsson J., Flicker E., Miketic S. et al. Prevention practices in patients with atrial fibrillation and neurological events: evidence for underutilization of anticoagulation //Eur. Heart J. 1999. — Vol.20, Abstr.Suppl. — P.665.
- Carr B., Hawley K., Channer K. Cardioversion of atrial fibrillation of recent onset with flecainide //Postgrad. Med. J. 1991. — Vol.67. — P.659−662.
- Catherwood E., O’Rourke D. Critical pathway management of unstable angina //Prog. Cardiovasc. Dis. 1994. — Vol.3. — P.121−148.
- Cerebral Embolism Task Force: Cardiogenic brain embolism: The second report of the Cerebral Embolism Task Force //Arch. Neurol. 1989. — Vol.46. — P.727−743.
- Challenge and potential for assuring quality health care for the 21st Century //www.ahcpr.gov/qual/21 stcena.htm.
- Chambers J. Is it safe to cardiovert atrial fibrillation without anticoagulation if the transoesophageal echocardiogram is normal? //Int. J. Cardiol. 1998. — Vol.63, N2. -P.107−109.
- Chambers J.B., de Belder M.A., Moore D. Echocardiography in stroke and transient ischaemic attack //Heart. 1997. — Vol.78, Suppl. 1. — P.2−6.
- Chassin M.R. Is health care ready for Six Sigma quality? //Milbank Qual. 1998. -Vol.76.-P.565−591.
- Cheah T.S. The impact of clinical guidelines and clinical pathways on medical practice: effectiveness and medico-legal aspects //Ann. Acad. Med. Singapore. 1998. -Vol.27, N4. — P.533−539.
- Chen S-A. Pulmonary vein ablation for atrial fibrillation: where do we stand, what more can we expect? // Hellenic. J. Cardiol. 2004. — Vol.45. — P. 129−131.
- Chu S., Cesnik B. Modelling computerised clinical pathways //Medinfo. 1998. -Vol.9, Pt.l. -P.559−563.
- Chun S., Sager P., Stevenson W. et al. Long term efficacy of amiodarone for maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter //Amer. J. Cardiol. 1995. — Vol.76. -P.47−50.
- Citrome L. Practice protocols, parameters, pathways and guidelines: a review //Adm. Policy Ment. Health. 1998. — Vol.25, N3. — P.257−269.
- Cleland J., Chattopadhay S., Khaud A. et al. Prevalence and incidence of arrhythmias and sudden death in heart failure //Heart Fail. Rev. 2002. — Vol.7. — P.229−242.
- Cleland J.G.F., Cowburn P.J., Falk R.H. Should all patients with atrial fibrillation receive warfarin? //Eur. Heart J. 1996. — Vol.17. — P.674−681.
- Clinical standards board for Scotland (2000) CSBS Standard coronary heart disease (CHD) — Secondary prevention following acute myocardial infarction-rehabilitation. hhh://www.clinicalstandards.org.
- Cochrane A., Siddins M., Rosenfledt F.L. et al. A comparison of amiodarone and digoxin for treatment of supreventricular arrhythmias after cardiac surgery //Eur. Cardiothorac Surg. 1994. — Vol.8. — P. 194−198.
- Cole L., Lasker-Hertz S., Grady G. et al. Structured care methodologies: tools for standardization and outcomes measurement //Nurs. Case Manag. 1996. — Vol.1. -P.160−172.
- Connolly S. Blood pressure and atrial fibrillation: potential benefits of blood pressure-lowering treatment //A Boehringer Ingelheim sponsored Satellite Symposium at the 27th International Stroke Conference, 2002, Febr., San-Antonio, USA. P.3−5.
- Connolly S.J., Hoffert D.L. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation //Amer. J. Cardiol. 1989. — Vol.63. — P. 817−819.
- Connolly S.J., Laupacis A., Gent M. et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study //J. Amer. Coll. Cardiol. 1991. — Vol.18. — P.349−355.
- Coplen S., Antman E., Berlin J. et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials //Circulation. 1990. — Vol.82. — P. 1106−1116.
- Corrado G., Tadeo G., Beretta S. et al. Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation //Chest. 1999. — Vol.115 — P. 140−143.
- Costeas C., Kassotis J., Blitzer M., Reiffei J. Rhytm management in atrial fibrillation with primary emphasis on pharmacological therapy. Pt 2 // PACE. — 1998. -Vol.21, PU.-P.742−752.
- Cotter G., Blatt A., Kalusi E. et al. Conversion of resent-onset paroxysmal atrial fibrillation to normal sinus rhythm: the affect on treatment and high dose amiodarone //Eur. Heart J. 1999.-Vol.20. — P. 1833−1842.
- Coumel P. Atrial fibrillation: one more sporting inconveniece? //Eur. Heart J. -2002.-Vol.23.-P.431−433.
- Coumel P. Autonomic arrhythmogenic factors in paroxysmal atrial fibrillation //Atrial fibrillation: mechanisms and therapeutic strategies /Eds. Olsson S.B. et al. New York: Futura Publishing Co.: Armonk, 1994. — P. 171−185.
- Corrado G., Sormani L., Tadeo G. Prevalence of atrial thrombi in patients with atrial fibrillation/flutter and subtherapeutic anticoagulation candidates to cardioversion IIEurop. Heart J. 2002. — Vol.4, Abstr. suppl. — P.238.
- Cowan J.C., Gardiner P., Reid D.S. et al. A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected acute myocardial infarction //J. Cardiovasc. Pharmacol. 1986. — Vol.8, N2. -P.252−256.
- Cox J. The surgical treatment of atrial fibrillation //J. Thorac.Cardiovasc. Surg. -1991.-Vol.101.-P.584−592.
- Cox J.L. Atrial fibrillation II. Rationale for surgical treatment. //J. Thorac. Cardiovasc. Surg. 2003. — Vol.126. — P. 1693−1699.
- Crijns H.J., Van den Berg M.P., Van Gelder I.C., Van Veldhusien D.J. Management of atrial fibrillation in the setting of heart failure //Eur. Heart J. 1997. -Vol.18, Suppl. C. -P.45C-49C.
- Crijns H.J., Van Gelder I.C., Tieleman R.G. Atrial fibrillation: antiarrhythmic therapy //Evidence based cardiology /Eds. Yusuf et al. London: BMJ Books, 1998. -P.527−543.
- Crijns H.J., Van Wijk. L.M., Van Gilst W.H. et al. Acute conversion of atrial fibrillation to sinus rhythm: Clinical efficacy of flecainide acetate. Comparison of two regiment //Eur. Heart J. 1988. — Vol.9. — P.634−638.
- Crombie J., Davis H., Abracham S. et al. Audit handbook improving health care through clinical audit. — Chichester- New York: Wiley, 1997.
- Crossing the quality chiasm: A new health system for 21st centure /Institute of Medicine. Washigton: National Academies press, 2001. — 337 p.
- Danias P.G., Caulfield T.A., Weigner M.J. at al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm //J. Amer. Coll. Cardiol. 1998. — Vol.31 -P.588−592.
- Daoud E.D., Bogun F., Goyal R. et al. Effect of atrial fibrillation on atrial refractoriness in humans //Circulation. 1996. — Vol.94. — P.1600−1606.
- Daoud E.G., Knight B.P., Weiss R. et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans //Circulation. 1997. -Vol.96. -P.1542−1550.
- Daoud E.G., Strickberger S.A., Man K.C. et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery // New Engl. J. Med. 1997. -Vol.337.-P.1785−1791.
- Darer J., Pronovost P., Bass E. Use and evaluation of critical pathways in hospitals //Effective Clinical Practice. 2002. — Vol.5. — P. l 14−119.
- Damiano R.J., McCarthy P.M., Gillinov A.M. et al. Prospective multicenter clinical trial of surgical pulmonary vien isolation for the treatment of atrial fibrillation //J. Amer. Coll. Cardiol. 2003. — Vol. 41 (Suppl.A). — 498A, Abstr. 1037−23.
- Dasbiens N. Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis // J. Amer. Geriatr. Soc. 2002. — Vol.50. -P.863−869.
- Database of abstracts reviews of effectiveness //The Cochrane Library, Oxford: Update Software. 2000. — Iss. 4. — № DARE-981 970.
- Database of abstracts reviews of effectiveness //The Cochrane Library, Oxford: Update Software. -2001. Iss. 1. -№ DARE-991 282.
- De Luca I., Sorino M., Del Salvatore B. et al. Importance of post-cardioversion transesophageal echocardiography for the timing of anticoagulation in atrial fibrillation: a 1 years follow-up // Eur. Heart J. 2002. — Vol.24. — Abstr. suppl. — P. 176.
- De Simkne A., Stabile G., Vitale D.F. et al. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who undervent electrical cardioversion //J. Amer. Coll. Cardiol. 1999. — Vol.34. — P.810−814.
- De Simone A., De Pasquale M., De Matteis C. et al. Verapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study) IIEur. Heart J. 2003. — Vol.24. — P. 1425−1429.
- Decker W., Goyal D., Boie E. A prospective, randomized trial of an emergency department observation unit for acute onset atrial fibrillation //Acad. Emerg. Med. -2003. Vol.10, N5. — P.543−544.
- Delamothe T. Wanted: guidelines that doctors will follow implementation is the problem //Br. Med. J. — 1993. — Vol.307. — P.218
- Delia Bella P., Tondo C. et al. Stratification and outcomes in patients with paroxysmal atrial fibrillation: pulmonary vien ablation versus linear lesions //Eur. Heart J. 2001. — Vol.3, Suppl. P. — P.33P -40P.
- Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (The ACUTE Multicenter Study). Steering and publications committees of the ACUTE study //Amer. J. Cardiol. 1998. — Vol.81, N7. — P.877−883.
- Di Viasi P., Scrofani R., Paje A. et al. Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation // Eur. Cardiothorac. Surg. 1995. -Vol.9. -P.587−591.
- Diener H. European Stroke Prevention Study II: dipyridamole and acetylsalicylic acid in the prevention of stroke //J. Neurol. Sei. 1996. — Vol.143. — P.1−13.
- Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation. Results of randomized, placebo controlled multicentre trial in 239 patient. // Eur Heart J. 1997. — 18(4). — P.649−654.
- Diker E., Aydogdu S., Ozdemir M. et al. Prevalence and predictors of atrial fibrillation in rheumatic heart disease //Amer. J. Cardiol. 1996. — Vol.77. — P.96.
- Disertori M., Padeletti L., Santini M. et al. Antitachycardia pacing therapies to terminate atrial tachyarrhytmias: the AT5000 Italian Registry //Eur. Heart J. 2001. -Vol.3, Suppl. P. -P.16P -24P.
- Donabedian A. The quality of care. How can it be assessed? // J. Amer. Med. Assoc. 1988. — Vol.260. — P.1743−1748.
- Donovan K.D., Dobb G.J., Lee K.Y. et al. Efficacy of flecainide for the reversion of acute onset atrial fibrillation //Amer. J. Cardiol. 1992. — Vol.70. — P.50A-54A.
- Donovan K.D., Power B.M., Hocking B.E. et al. Intravenous flecainide versus amiodarone resent onset atrial fibrillation //Amer. J. Cardiol. 1995. — Vol.75. — P.693−697.
- Doran K., Sampson B., Status R. et al. Clinical pathway across tertiary and community care after an interventional cardiology procedure //J. Cardivasc. Nes. 1997 -Vol.ll.-P.l-14.
- Dorian P., Mangat I. Restoring sinus rhythm in atrial fibrillation //J. Amer. Coll. Cardiol. 2003. — Vol.42. — P.30−32.
- Duff L.A., Kitson A.L., Seers K., Humphris D. Clinical guidelines: an introduction to their development and implementation //J. Adv. Nurs. 1996. — Vol.23, N5. — P.887−895.
- EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke //Lancet. -1993.-Vol.342.-P.1255−1262.
- Eisenberg J., Forlini J., Joljis J. et al. AHA/ACC 2nd Scientific Forum on Quality of Care and Outcomes research in Cardiovascular Disease and Stroke //www.medscape.com/ Medscape/CNO/2000/AHA-ACC-CS.
- Elhendy A., Gentile F., Khandheria B. et al. Embolic complications of electrical cardioversion. A study of 834 procedures from one centre //Eur. Heart J. 2000. -Vol.21, Abstr. Suppl. — P.503.
- Ellenbogen K., Stambler B., Wood M. et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and flutter: A dose response study //J. Amer. Coll. Cardiol. 1996. — Vol.28. -P.130−136.
- Ellinor P., Macrae C. The genetics of atrial fibrillation //J. Cardiovasc. Electrophysiol. -2003. -Vol.14. P.1007−1009.
- Engelmann M. Quality of life in nonpharmacologic treatment of atrial fibrillation //Eur. Heart J. 2003. — Vol.24. — P.1387−1400.
- Epstein A.E. Atrial fibrillation: non-pharmacologic therapies //Yusuf S. Evidence based cardiology. London: BMJ Books, 1998. — P.553−561.
- Falk R.H. Management of atrial fibrillation radical reform or modest modification? //New Engl. J. Med. — 2002. — Vol.347, N23. — P. 1883−1884.
- Falk R.H. Proarrhythmia in patients treated for atrial fibrillation or flutter //Ann. Intern. Med. 1992. — Vol.117. — P. 141−150.
- Falk E.H., Knowlton A.A., Bernard S.A. et al. Digoxin for converting resent-onset atrial fibrillation to sinus rhythm: A randomized double-blinded trial //Ann. Intern. Med. -1987.-Vol.106.-P.503−506.
- Falk R., Pollak A., Singh S.N., Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent for the termination of sustained atrial fibrillation or flutter //J. Amer. Coll. Cardiol. 1997. — Vol. 29. — P.385−390.
- Fang M., Stafford R., Ruskin J., Singer D. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation //Arch. Intern. Med. 2004. -Vol.164. -P.55−60.
- Farshi R., Kistner D., Sarma J. et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens //J. Amer. Coll. Cardiol. 1999. — Vol.33. — P.304−310.
- Fatkin D., Kelly R.P., Feneley M.P. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo //J. Amer. Coll. Cardiol. 1993. — Vol.22. -P.1359−1366.
- Fenster J., Comess K.A., Marsh R. et al. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion //Amer. Heart J. 1983. — Vol.106. -P.501−504.
- Fetsch T., Engberding R., Koch H.P. et al. How reliable are symptoms for detection of atrial fibrillation in clinical routine? Results of the PAFAC trial //Eur. Heart J. 2002. — Vol.23, Abstr. suppl. — P.662, Abstr. P3461.
- Fihn S., Callahan C., Martin D. et al. The risk for and severity of bleeding complications in eldery patiens treated with warfarin //Ann. Intern. Med. 1996. -Vol.124. -P.970−979.
- Flaker G., Blacksheer J., McBride R. et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Investigators //J. Amer. Coll. Cardiol. 1992. — Vol.20 — P.527−532.
- Flaker G., McGowan D.J., Boechler M. et al. Underutilization of anthithrombotic therapy in elderly patients with atrial fibrillation //Amer. Heart J. 1999. — Vol.137: -P.307−312.
- Folino A. Incidence of atrial fibrillation in patients with different mode of pacing. Long-term follow-up //PACE. 1998. — Vol.21, Pt.2. — P.260−263.
- Feiberg J., Scharling H., Truelsen T. et al. Atrial fibrillation: a more potent risk factor for stroke and cardiovascular death in women than in men. The Copenhagen city heart study // Eur. Heart J. 2003. — Vol.24. — P. 1437.
- Fresco C., Proclemer A. Clinical challenge II: Management of recent onset atriall fibrillation //Eur. Heart J. 1996. — Vol.17. — P.41−47.
- Fresco C, Proclemer A., Pavan A. et al. Intravenous propafenone in paroxysmal atrial fibrillation: A randomized, placebo-controlled, double-blind, multi-center clinical trial //Clin.Cardiol. 1996. — Vol.19. — P.409−412.
- Frost L., Engholm G., Moller H. et al. Decrease in mortality in patients with a hospital diagnosis of atrial fibrillation in Denmark during the period 1980−1993 //Eur. Heart J. 1999. — Vol.20. — P. 1592−1599.
- Frost L., Molgaard H., Christiansen E.H. et al. Atrial fibrillation and flutter after coronary artery bypass surgery: epidemiology, risk factors and preventive trials //Int. J. Cardiol. 1992. — Vol. 36. — P.253−261.
- Fujimura O., Klein G J., Yee R., Sharma A.D. Mode of oncet of atrial fibrillation in Wolff-Parkinson-White: how important is the accessory pathway? //J. Amer. Coll. Cardiol. 1990. — Vol.15. — P. 1082−1086.
- Furberg C., Psaty B., Manolio T. et al. Prevalence of atrial fibrillation in elderly subject (the Cardiovascular Heart Study) //Amer. J. Cardiol. 1994. — Vol.74. — P.236−241.
- Gage B.F., Boechler M., Doggette M.A. et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation //Stroke. 2000. — Vol.31. — P.822−827.
- Gage B.F., Cardinalli A.B., Owens D.K. Cost-effectiveness of preference-based antitrombotic therapy for patients with nonvalvular atrial fibrillation //Stroke. 1998. -Vol.29, N6. -P.1083−1091.
- Gallagher M.G., Camm A.J. Classification of atrial fibrillation //Pacing Clin. Electrophysiol. 1997. — Vol.20. — P. 1603−1605.
- Galperin J., Molino R.T., Elizari M. et al. Amiodarone in chronic atrial fibrillation. A controlled, double blind study for its reversion and maintenance of normal sinus rhythm // J. Amer. Coll. Cardiol. 2000. — Vol.35, Iss.2. — P. l 18.
- Ganz L.I. Atrial fibrillation, atrial flutter, and other supraventricular tachyarrhytmias //Hospital medicine /Eds. R. Wachter et al. Philadelphia etc.: Lippincott, Williams & Wilkins, 2000. — P.263−274.
- Ganz L.I. Idiopathic atrial fibrillation: therapeutic strategies //Cardiol, review. -2000- Jan. -P.2−11.
- Garrido M., Williams M., Vigilance D. et al. Surgical ablation of atrial fibrillation // J. Amer. Coll. Cardiol. 2003. — Vol.41, Suppl. A. — P.106A.
- Gaynor S., Prasad S., Schuessler R. et al. Long-term results of the surgical treatment of atrial fibrillation: predictors of late recurrence // J. Amer. Coll. Cardiol -2003. Vol.41, suppl. A.- P.498A.
- Gentile F., Elhendy A., Khandheria B.K. et al. Safety of electrical cardioversion in patients with atrial fibrillation //Mayo Clin. Proc. 2002. — Vol.77. — P.897−904.
- Gentiii C., Giordano F., Alois A. Efficacy of intravenous propafenone in acute atrial fibrillation complicating open heart surgery //Amer. Heart J. 1992. — Vol.123. -P.1225−1228.
- Geller J., Reek S., Timmermans C. et al. Treatment of atrial fibrillation with implantable of atrial defibrillator: long-term results // Europ. Heart J. 2003. — Vol.24. -P.2083−2089.
- Gillinov A.M., Mccarthy M., Marrouche N., Natale A. Contemporary surgical treatment for atrial fibrillation // PACE. 2003. — Vol.26, part II. — P.1641−1644.
- Godtfredsen J., Falk R. Cardiac arrhythmias. A clinical approach. St. Louis etc.: Mosby, 2003. — 452 p.
- Godtfredsen J. Stroke in atrial fibrillation: epidemiology, risk factors and prognosis //Godtfredsen J., Falk R. Cardiac arrhythmias. A clinical approach. St. Louis etc.: Mosby, 2003. — P. 135−145.
- Gold L., Parry D., Raftery J. et al. An assessment of potential indicators of clinical effectiveness. Birmingham: University of Birmingham, 1998.
- Golderg H.I., Neighbor W.E., Hirsch I.B. et al. Evidence-based management: using serial firm trials to improve diabetes care quality //J. Quality Improv. 2002. -Vol.28, N4.-P. 155−166.
- Goldstein L.B., Adams C.R., Becker K. et al. Primary prevention of ischemic stroke. A statement for Healthcare Professionals from the stroke council of the American Heart Association //Circulation. 2001. — Vol. 103. — P. 163−182.
- Gonzbiez-Alujas T., Evangelista A., Mateos M. et al. Predictors of left atrium thrombus persistence assessed by transesophageal echocardiography.// Eur. Heart J. -2000. Vol.21. — Abstr. Suppl. — P.7.
- Gottlieb L.K., Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice //Arch. Intern. Med. 1994. -Vol.12.-P.1945−1953.
- Goy J.J., Maendly R., Gribic M. et al. Cardioversion with flecainide in patients with atrial fibrillation of resent onset //Eur. J. Clin Pharmacol. 1985. — Vol.27. — P.737−738.
- Graham N.O. Quality in health care: Theory, application, and evolution. -Gaithersburg (Md.): Aspen, 1995. 366 p.
- Granata A.V., Hillman A.L. Competing practice guidelines: using cost-effectiveness analysis to make optimal decisions //Ann. Intern. Med. 1998. — Vol.128. -P.56−63.
- Grant A.O. Recent advances in the treatment of arrhythmias //Circulation. J. -2003.-Vol.67.-P.651−655.
- Greengold N.L., Weingarten S.R. Developing evidence-based practice guidelines and pathways: the experience at the local hospital level //Joint Comm. J. Qual. Improv. -1996 Vol.22, N6. — P.391−402.
- Grenshaw B.S. Ward S.R., Granger C.B. et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO I experience //J. Amer. Coll. Cardiol. 1997. -Vol.30.-P.406−413.
- Gribenow R., Kedmer L.I., Wagner J. et al. Exclusion of atrial thrombi by transesophageal echocardiography predicts low risk of embolic events after cardioversion of atrial fibrillation //Eur. Heart J. 1999. — Vol.20, Abstr. Suppl. — P.227.
- Grimshaw J., Freemantle N., Wallace S. et al. Developing and implementing clinical practice guidelines //Qual. Health Care. 1995. — Vol.4. — P.55−64.
- Grimshaw J., Russell I. Achieving health gain through clinical guidelines. I-Developing scientifically sound guidelines //Qual. Health Care. 1993. — Vol.2. — P.243−248.
- Grogan M., Smith H.C., Gersh B.J., Wood D.L. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy //Amer. J. Cardiol. 1992. — Vol.69. — P.1570−1573.
- Gronefeld G., Ehrlich J., Hohnloser S. Comparison of outpatients vs inpatients direct current cardioversion of atrial fibrillation: safety, efficacy and cost savings //Eur. Heart J.-2003.-Vol.5, Suppl. H. P.19H-24H.
- Gronefeld G., Hohnloser S. Quality of life in atrial fibrillation: an increasingly important issue //Eur. Heart J. 2003. — Vol.5, Suppl. H. — P. 25H-33H.
- Gronefeld G., Lilienthal J., Kuck K.H. et al. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study //Eur. Heart J. 2003. — Vol.24. — P.1430−1436.
- Guarnieri T., Nolan S., Gottlieb S.O. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: The Amiodarone Reduction in Coronary Heart (ARCH) Trial //J. Amer. Coll. Cardiol. 1999. — Vol.34. — P.343−347.
- Guide to inpatient quality indicators: Quality of care in hospitals volume, mortality, and utilization //www.ahrg.gov. — June, 2002.
- Guide to quality assurance /The Joint Commiss. on Accreditation of Healthcare organizations. Chicago (111.), 1988. — 875 p.
- Guidelines for clinical practice: from development to use /Institute of Medicine- Field M.J., Lohr K.N., eds. Washington: National Academy Press, 1992. — 165 p.
- Guiraudon G.M., Klein G.J., Guiraudon C.M., Yee R. Surgical treatment of atrial fibrillation what new? Long-term follow up. www //Heartweb.org/ heartweb/1196/afib0002.htm.
- Guo G.B., Ellenbogen K.A., Wood M.A., Stambler B.S. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability //J. Amer. Coll. Cardiol. 1996. — Vol.27. -P.1083−1089.
- Gustafsson K., von Bahr C., Dahlqvist R., Edhag O. Long-term effects related to dose and concentration of disopyramide in in atrial fibrillation //Circulation. 1986. -Vol.74, Suppl. 2.-P. 101.
- Haissaguerre M., Sanders P., Hocini M. et al. Pulmonary veins in the substrat for atrial fibrillation. The «Venous wave» hypothesis //J. Amer. Coll. Cardiol. 2004. — Vol. 43. -P.2290−2292.
- Haissaguerre M., Jais P., Shah D.C. et al. Electrophysiological and point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci //Circulation. -2000. Vol.101. — P. 1409−1417
- Haissaguerre M., Jais P., Shah D.C. et al. Spontaneous initation of atrial fibrillation by ectopic beats originating in the pulmonary veins //New Engl. J. Med. -1998. Vol.339. — P.659−666.
- Halien M.O., Huttunen M., Paakkinen S. et al. Comparison of Sotalol with digoxin- quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol -digoxin quinidine trial //Amer. J. Cardiol. 1995. — Vol.76. — P.495−498.
- Halpern S.W., Ellrodt G., Singh B.N. Efficacy of intravenous procainamide infusion in conversion atrial fibrillation to sinus rhythm. Relation to left atrial size //Br. Heart J. 1980. — Vol.44. — P.589−595.
- Halligan S., Gersh B., Brown R. et al. The natural history of lone atrial fibrillation // Ann. Intern. Med. 2004. — Vol.140. — P.265−268.
- Hart R.G. Atrial fibrillation and stroke prevention //New Engl. J. Med. 2003. -Vol.349. -P.1015−1016.
- Hart R.G., Benavente O., McBride R., Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis //Ann. Intern. Med. -1999.-Vol.131.-N1.-P.492−501.
- Hart R., Halperin J.L. Atrial fibrillation and stroke: Concepts and controversies //Stroke. -2001. Vol.32. -P.803−808.
- Hart R., Halperin J.L. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention //Ann. Intern. Med. 1999. — Vol. 131. — P.688−695.
- Hart R. G, Halperin J.L., Pearce L.A. et al. Lessons from the stroke prevention in atrial fibrillation trial //Ann. Intern. Med. 2003. — Vol.138. — P.831−838.
- Hart R.G., Palacio S., Pearce L.A. Atrial fibrillation, stroke, and acute antithrombotic therapy. Analysis of randomized clinical trials //Stroke. 2002. — Vol.33. -V 2122−2121.
- Hart R.G., Pearce L.A., McBride R. et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation. Analysis of 2012 participants in the SPAF I-III clinical trials //Stroke. 1999. — Vol.30. — P. 1223−1229.
- Hartel G., Louhija A., Konttinen A., Halonen P. Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation //Br. Heart J. -1970,-Vol.32.-P.57−60.
- Hayes W.S. An opportunity to improve the medical care system: Independent review //Healthplan. -2001. Vol.42, N6. — P. 12−19.
- Heisel A., Jung J. The atrial defibrillator: a stand alone device or part of a combined dual-chamber system //Amer. J. Cardiol. 1999. — Vol.83. — P.218D-226D.
- Hillestad L., Bjerkelund C., Dale J. et al. Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation: A controlled clinical study //Br. Heart J. 1971. — Vol.33. -P.518−521.
- Hirsh J., Fuster V., Ansell J., Halperin J. American Heart Association /American College of Cardiology foundation guide to warfarin therapy //Circulation. 2003. -Vol.107.-P.1692−1711.
- Hobbs W.J., Fynn S., Todd D.M. et al. Reversal of atrial electrical remodeling after cardioversion of persistent atrial fibrillation //Circulation. 2000. — Vol.101. -P.1145−1151.
- Hobbs W.J., Van Gelder I.C., Fitzpatrick A.P. et al. The role of atrial electrical remodeling in the progression of focal atrial ectopy to persistent atrial fibrillation //J. Cardiovasc. Electrophysiol. 1999. — Vol.10. — P.866−870.
- Hoffart N., Cobb A.K. Assessing clinical pathways use in a community hospital: It depends on what «use» means //Jt. Comm. J. Qual. Improv. 2002. — Vol.28, N4. -P.167−179.
- Hoffmann E., Janko S., Steinbeck G. et al. Onset scenarios of paroxysmal atrial fibrillation using new diagnostic pacemaker functions //PACE. 2000. — Vol.23, Pt.2. -P.656. — Abs. 415.
- Hofman P.A. Critical path method: an important tool for coordinating critical care //J. Qual. Improvem. 1993. — Vol.19. — P.235−246.
- Hoekstra E.H., Hagens V.E., Kamp O. et al. Impotance of side effects of antiarrhythmic drugs to failure of rhythm control in the RACE study // Eur. Heart J. -2003.-Vol.24.-P.514.
- Hohnloser S.H., Kuck K.H. Randomized trial of rhythm or rate control in atrial fibrillation: the Pharmacologic Intervention in Atrial Fibrillation (PIAF) trial //Eur. Heart J. 2001. — Vol.22. — P.801−802.
- Hohnloser S.H., Van de Loo A., Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of Sotalol versus quinidine //J. Amer. Coll. Cardiol. 1995. — Vol.26. — P.852−858.
- Horn S.D. Sharkey S.S., Rimmasch H.L. Clinical practice improvement. A methodology to improve quality and decrease cost in health care //Oncol. Iss. 1997. — Vol.12.-P.16−20.
- Horstkotte D. Arrhythmias in the natural history of mitral stenosis //Acta. Cardiol. 1992.-Vol.47.-P.105−113.
- Hou Z., Chang.M., Chen C. et al. Acute treatment of recent onset atrial fibrillation and flutter with a tailored dosing regiment of intravenous amiodarone //Eur. Heart J. -1995.-Vol.16.-P.521−528.
- Howard P. Ibutilide: an antiarrhythmic agent for the treatment of atrial flutter or fibrillation //Ann. Pharmacol. Ther. 1999. — Vol.83. — P.58−61.
- Huang J.I., Wen Z.C., Lee W.L. et al. Changes of autonomic tone before the onset of paroxysmal atrial fibrillation //Int. J. Cardiol. 1998. — Vol.66. — P.275−283.
- Humphries K.H., Kerr C.R., Connoly S.J. et al. New-onset atrial fibrillation: sex differences in presentation, treatment and outcome //Circulation. 2001. — Vol.103. -P.2365−2370.
- Hylek E., Go A., Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and morality in atrial fibrillation //New Engl. J. Med. 2003. — Vol.349. -P.1019−1026.
- Ibarra V.L. Titler M.G., Reiter R.C. Issues in the development and implementation of clinical pathways //AACN Clin Issues. 1996. -Vol.7, N3. — P.436−447.
- Innes G.D., Vertesi L., Dillon E., Metcalfe C. Effectiveness of verapamil -quinidine versus digoxin quinidine in the emergency department treatment of paroxysmal atrial fibrillation //Ann. Emerg. Med. — 1997. — Vol.29. — P.126−134.
- Jahangir A., Munger T., Packer D., Crijns H. Atrial fibrillation //Cardiac arrhythmia. Mechanisms, diagnosis, management /Podrid P.J., Kowey P.R., eds. 2nd ed. — Philadelphia: Lippincott Williams & Wilkins, 2001. -P.457−499.
- Jais P., Haissaguerre M., Shuh D. et al. A focal source of atrial fibrillation treated by direct radiofrequency ablation //Circulation. 1997. — Vol.95. — P.572−576.
- Jais P., Shuh D., Made L. et al. Radiofrequency ablation for atrial fibrillation //Eur. Heart J. 2003. — Vol.5, Suppl. H. — P.34H -39H.
- Jayachandran J.V., Sih H. J., Winkle N. et al. Atrial fibrillation produced by prolonged rapid atrial pacing is associated with heterogeneous changes in atrial sympathetic innervation //Circulation. 2000. — Vol.101. — P. l 185−1191.
- Joint Commission on Accreditation of Healthcare Organization. Characteristics of clinical indicators //Quarterly Review Bulletin. 1989. — Vol.15, N11. — P.330−339.
- Joint Commission on Accreditation of Healthcare Organizations (JCAHO). Primer on indicator development and application. Measuring quality in health care. Oakbrook Terrace: JCAHO, 1990.
- Jonsson B. Measurement of health outcome and associated costs in cardiovascular disease //Eur. Heart J. 1996. — Vol.17, Suppl. A. -P.2−7.
- Jordaens L., Missault L., Germonpre E. et al. Delayed restoration of atrial function after conversion of atrial flutter by pacing or cardioversion //Amer. J. Cardiol. 1993. -Vol.71. -P.63−67.
- Juran J.M. Juran on planning for quality. New York: Free Press, 1988. — 538 p.
- Juul-Moller S., Edvardsson N., Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation //Circulation. 1990. — Vol.82. — P. 1932−1939.
- Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates //Amer. J. Cardiol. 1998. — Vol.82. — P.2N-9N.
- Kapral M., Silver F. Echocardiography for the detection of cardiac source of embolus inpatients with stroke //Canad. Med. Assoc. J. 1999. — Vol.161. -P.989−991.
- Karlson B., Torstensson I., Abjorn C. et al. Disopyramide in the maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation. A placebo-controlled one-year follow-up study //Eur. Heart J. 1988. — Vol.9. — P.284−290.
- Kaye M., Dyason M. Benchmarking for strategic advantage //44th European Quality Congress Proceedings. 2000. — Vol.1. — P.58−66.
- Kereiakkes D.J. Dawning of a new era in cardiovascular medicine: Applying evidence-based medicine to real-life practice //www.medscapr.com/Medscape/cardiology/TreatmentUpdate/2000/tu04/public/toc-tu04.htm.
- Kerin N., Faitel K., Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation //Arch. Intern. Med. 1996. — Vol.156. — P.49−53.
- Kerr C.R. Anticoagulants are underused in the treatment of atrial fibrillation and flutter //Evidence-based Cardiovas. Med. 1999. — Vol.3, N2. — P.322−325.
- Kerr E., Asch S., Hamilton E., McGlynn E. Quality of care for general medical conditions: A review of the literature and quality indicators. www.rand.org/publications/MR/MR1280. P.49−67.
- Kerr C., Boone J., Connolly S. et al. Follow-up of atrial fibrillation. The experience of the Canadian registry of atrial fibrillation //Eur. Heart J. 1996. — Vol.17, Suppl. C. -P.48−51.
- Khairy P., Nattel S. New insights into the mechanisms and management of atrial fibrillation //Canad. Med. Assoc. J. 2002. — Vol.167, N.9. — P. 1012−1020.
- Khaud A., Cleland J., Deedwania P. Prevention of and medical therapy for atrial fibrillation in heart failure //Heart Fail. Rev. 2002. — Vol.7. — P.267−283.
- Khand A., Rankin A., Martin W. et al. Carvedilol or digoxin for the treatment of atrial fibrillation in heart failure patients? //Eur. Heart J. 2000. — Vol.21, Suppl. -P.740.
- Kibbe D. A guide to finding and evaluating best practice health care information on the Intrenet: The truth is out there?, Section I: Who is seeking best practices on the Internet? //www.futurehealthcare.com
- Kimura K., Minematsu K., Wada K. et al. Clinical characteristics in transient ischemic attack patients with atrial fibrillation //Intern. Med. 2003. — Vol.42, N3. -P.255−258.
- Kingston M. A guide to benchmarking and best practice terminology //http://best4health.org/resource center/articles/Kingston.
- Kirchner J., Soderberg B. Atrial fibrillation: Clues to diagnosis and treatment //Hospital Medicine. 1999. — Vol.35. — P. 14−21.
- Kitchiner D., Davidson C., Bundred P. Integrated care pathways: effective tools for continuous of clinical practice //J. Eval. Clin. Pract. 1996. — Vol.2, N1. — P.65−69.
- Klein E.A. Assessment of Cardioversion Using Transesophageal Echocardiography multicenter study (ACUTE I): Clinical outcomes at eight weeks //J. Amer. Coll. Cardiol. 2000. — Vol.36. — P.324.
- Klein E.A., Grimm R.A., Black I.W. et al. Cardioversion guided transesophageal echocardiography: the ACUTE pilot study: a randomized, controlled trial //Ann. Intern. Med. 1997. — Vol.126. — P.200−209.
- Klein E.A., Grimm R.A., Murray R.D. et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation //New. Engl. J. Med. -2001. Vol.344. -P.1411−1420.
- Klein E.A., Murray R.D., Grimm R.A. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation //J. Amer. Coll. Cardiol. 2001. -Vol.37. -P.691−704.
- Koca V., Bozat T., Akkaya V. et al. Left atrial thrombus detection with multiplane transesophageal echocardiography: An echocardiographic study with surgical verification //J. Heart Valve Dis. 1999. — Vol.8. — P.63−66.
- Kochiadakis G.E., Igoumenidis N.E., Parthenakis F.I. et al. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized controlled study //J. Amer. Coll. Cardiol. 1999. — Vol.33. — P.966−971.
- Kochiadakis G.E., Igoumenidis N.E., Marketou M.E. et al. Procainamide-propafenone- amiodarone: which is preferred for the conversion of recent onset atrial fibrillation // Europ. Heart. J. 2000. — Vol.21. — P.472.
- Kottkamp H., Li J., Piorkowski C.H. et al. Left atrial substrate modification to cure atrial fibrillation: a prospective study on the efficiency of linear and circular nonisolating lession lines //Europ. Heart. J. 2003. — Vol.24. — P.391.
- Kohn L.T., Corrigan J.M., Donaldson M.S., eds. To err is human. Building a safer health system. Committee on Quality of Health Care in America. Institute of Medicine. -Washington: Academy Press, 1999.
- Kopecky S.L., Gersh B.J., McGoon M.D. et al. The natural history of lone atrial fibrillation. A population-based study over three decades //New Engl. J. Med. 1987. -Vol.317. -P.669−674.
- Koudstaal P.J. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and history of stroke or transient ischemic attacks (Cochrane review) //Cochrane Library. 2000. — Iss.3.
- Krahn A.D., Manfreda J., Tate R.B. et al. The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Manitoba Follow-up study //Amer. J. Med. -1995.-Vol.98.-P.476−84.
- Kuhlkamp V., Schmid F., Risler T., Seipel L. Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation //Int. J. Cardiol. 1991. -Vol.31. -P.65−69.
- Labovitz A.J., Bransford T.L. Evolving role of echocardiography in the management of atrial fibrillation //Amer. Heart J. 2001. — Vol. 141. — P.518−527.
- Lagoe R.J., Aspling D.L. Benchmarking and clinical pathway implementation on a multihospital basis //Nurs. Econ. 1997. — Vol. 15. -P. 131−137.
- La Pointe N.A., Pamer C.A., Kramer J.M. New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance //Pharmacotherapy. 2003. — Vol. 23. — P. 1316−1321.
- Larbuisson R., Venneman I., Stiels B. The efficacy and safety of intravenous of propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery //J. Cardioth. Vas. Anesth. 1996. — Vol.10. -P.229−234.
- Laupacis A., Albers G., Dalen J. et al. Antithrombotic therapy in atrial fibrillation //Chest. 1998. — Vol.114, Suppl. -P.579S-589S.
- Laupacis A., Cuddy T.E. Prognosis of individuals with atrial fibrillation //Can. J. Cardiol. 1996. — Vol. 12A — P. 14A-16A.
- Lawrence D. The future of health care //Medscape, 2000.
- Leape L.L. Error in medicine //J. Amer. Med. Assoc. 1994. — Vol.272. — P. 18 511 857.
- Leape L.L., Bates D.W., Cullen D.L. et al. System analysis of adverse drug events //J. Amer. Med. Assoc. 1995. — Vol.274. -P.35−43.
- Lee S., Chen S., Chiang C. et al. Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind randomized trial //J. Intern. Med. 1996. — Vol.239. — P.253−260.
- Lesar T.S. Recommendations for reducing medication errors //Medscape. Pharmacists, 2000.
- Le Heuzey J-Y., Paziaud O., Piot O. et al. Cost of care distribution in atrial fibrillation patients: The COCAF study // Amer. Heart. J. 2004. — Vol.147. — P.121−126.
- Levy S. Epidemiology and classification of atrial fibrillation //J. Cardiovasc. Electrophysiol. 1998. — Vol.9, Suppl. 8. -P.78S -82S.
- Levy S., Breithardt G., Campbell R. et al. Atrial fibrillation: current knowledge and recommendations for management. Working group of Arrhythmias of the European Society of Cardiology report //Eur. Heart J. 1998. — Vol.19. — P.1294−1320.
- Levy S., Lauribe P., Dolla E. et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation //Circulation. 1992. — Vol.86. -P.1415−1420.
- Levy S., Maarek M., Coumel P. et al Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study //Circulation. 1999. -Vol.99. -P.3028−3035.
- Levy S., Ricard P., Lau C. et al. Multicenter low energy transvenous atrial de fibrillation (XAD) trial results in different subsets of atrial fibrillation IIJ. Amer. Coll. Cardiol. 1997. — Vol.29. — P.750−755.
- Letelier L., Udol K., Ena J. et al. Effectiveness of amiodaron for conversion of atrial fibrillation to sinus rhythm: a meta-analysis //Arch. Intern. Med. 2003. — Vol. 163.-P. 777−785.
- Li H., Easley A., Barrington W. et al. Evaluation and management of atrial fibrillation in the emergency department //Emerg. Med. Clin. North. Amer. 1998. -Vol. 16.-P. 389−403.
- Lightowlers S., McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke //Stroke. 1998. — Vol.29, N9.-P. 1827−1832.
- Lin HJ., Wolf P.A., Kelly-Hayes V. et al. Stroke severity in atrial fibrillation //The Framingham Study. 1996. — Vol.27. — P.1760−1764.
- Lip GY., Beevers DG. ABCs of atrial fibrillation: hystory, epidemiology and important of atridl fibrillation //Br. Med. J. 1995. — Vol.311. — P. 1361−1363.
- Lip G.Y., Lip P.L., Zarifis J. et al. Fibrin D-dimer and b-thromboglobulin as markers of thrombogensis and platelet activation in atrial fibrillation //Circulation. -1996.-Vol.94.-P.425−431.
- Li-Saw-Hee F., Blan A., Gurney D. Is there difference in thrombogenesis between patients with paroxysmal, persistent and permanent atrial fibrillation? 111. Amer. Coll. Cardiol. 2000. — Vol.35, Suppl. A. — P.281.
- Luderitz B., Yung W. Quality of life of patients with atrial fibrillation //Progress in clinical pacing /Santini M. (ed). Armonk (N.Y): Futura Publishing, 1996. — P.253−262.
- Lumsdon K., Hagland M. Mapping care //Hospitals & Health Network. 1993. -Vol.67, N20.-P.34−40.
- Lundstrom T., Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: Effects of diltiazem and verapamil //J. Amer. Coll. Cardiol. -1990.-Vol.16.-P.86−90.
- Madrid A.H., Moro C., Marin-Huerta E. et al. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation //Eur. Heart J. 1993. — Vol.14 -P.l 127−1131.
- Malouf J.F., Ammash N.M., Chandrasekaran K. et al. Critical appraisal of transesophageal echocardiography in cardioversion of to atrial fibrillation //Amer. J. Med. 2002. — Vol. 113, N7. — P.587−595.
- Mandapai R., Skanes A., Chen J. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart //Circulation. 2000. — Vol.101. — P. 194−199.
- Manning W, Weintraub R. Accuracy of transesophageal echocardiography for identifying left atrial thrombi //Ann. Intern. Med. 1995. — Vol.123. — P.817−822.
- Manning W.J., Zimetbaum P.J. Direct current cardioversion of atrial fibrillation -the next 40 years //Mayo Clinic Proc. 2002. — Vol.77. — P.895−896.
- Man-Son-Hung M., Laupacis A. Balancing the risk of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation //Arch. Intern. Med. 2002. — Vol.162. -P.541−550.
- Massoud R., Askov K., Reinke J. et al. A modern paradigm for improving healthcare quality //www.gaproject.org.
- Matsuda M., Matsuda Y., Yamagishi T. et al. Effects of digoxin, propranol, and verapamil on exercise in patients with chronic isolated atrial fibrillation //Cardivasc. Res. -1991. Vol.25. -P.453−457.
- Manios E.G., Kanoupakis E.M., Kaleboubas M.D. et al. Changes in atrial properties following cardioversion of chronic atrial fibrillation: relation with recurrence //Europ. Heart J. 2000. — Vol.21. — P.471.
- McAlister H.F., Luke R.A., Whitlock R.M. et al. Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operation //J. Thorac. Cardiovasc. Surg. 1990. — Vol.99. -P. 911−918.
- McGowan J.E. Success, failures and costs of implementing standards in the USA lessons for infection control //J.Hosp. Infect. — 1995. — Vol.30, Suppl. — P.76−87.
- Medical errors: the scope of the problem. An epidemic of errors //www.ahcpr.gov./qual/errback.htm.
- Medical errors: The scope of the problem. Fact sheet. Rockville (Md.): Agency for Healthcare Research and Quality, 2000.
- Middleton S., Barnett J., Reeves D. What is an integrated care pathway? //What is. .bulletins. 2001. Vol.3, N3.
- Miller K.E. Intermittent atrial fibrillation and stroke risk //Amer. Family Physician. 2000. — Vol. 1. — P. 1.
- Mills P., Weeks W., Surrott-Kimberly B. A multihospital safety improvement effort and the dissemination of new knowledge //Jt. Comm. J. Qual. Saf. 2003. -Vol.29, N3. -P.124−133.
- Moe G.K. A conceptual model of atrial fibrillation //J. Electrocardiol. 1968. -Vol.1.-P.145−146.
- Monti L., Sambola A., Brugada J. et al. Long-lasting sport practice and lone atrial fibrillation //Eur. Heart J. 2002. — Vol.23. — P.477−482.
- Montoye C.K., Mehta R.H., Baker P.L. et al. A rapid-cycle collaborative model to promote Guidelines for acute myocardial infarction //Jt. Comm. J. Qual. Saf. 2003. -Vol.29, N9. -P.468−478.
- Moores K.G. Evidence-based clinical practice guidelines //Drug Benefit Trends -1997-Vol.9.-P.37−45.
- Moos A.N., Wurdeman R., Mohiuddin S.M. et al. Esmolol versus Diltiazem in the treatment of postoperative atrial fibrillation/ atrial flutter after open heart surgery //Amer. Heart J. 2000. — Vol. 140. — P. 176−180.
- Moser D., Frazier S.K., Worster P.L., Clarke J. The role of the critical care nurse in preventing heart failure after acute myocardial infarction //Amer. Heart J. 1998. -Vol.135. -P.353−360.
- Moxey E.D., O’Connor J.P., White E. et al. Developing a quality measurement tool and reporting format for long term care //J. Qual. Improv. 2002. — Vol.28, N4. -P. 180−192.
- Murgatroyd F.D., Gibson S.M., Baiyan X. et al. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation // Circulation. 1999. -Vol.99.-P.2765−2770.
- Nabitz U., Klazinga N., Walburg J. The EFQM excellence model: European and Dutch experiences with the EFQM approach in health care //Intern. J. Quality in Health Care. 2000. — Vol.12, N3. — P. 191−201.
- Naeearelli G.V., Wolbrette D.L., Khan M. et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials //Ajner. J. Cardiol. 2003. — Vol.91, N20. — P. 15D-26D.
- Noc M., Stajer D., Horvat M. et al. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm //Amer. J. Cardiol. -1990,-Vol.66.-P.679−680.
- Nyberg D., Marshke P. Critical pathway tools for continuous quality improvement //Nuts. Admin. Q. 1993. — Vol.17, N3. -P.62−69.
- O’Keeffe D., Nicholls D., Morton P. et al. Maintenance of sinus rhythm after elective cardioversion from chronic atrial fibrillation: amiodarone compared with quinidine //Br. Heart J. 1984. — Vol. 151. — P. 103.
- Oakland J.S., Porter L.J. Total quality management. Oxford: ButterworthHeinemann, 1995. — 288 p.
- Ochs H.R., Eichelbaum M., Greenblatt D.J. Diltiazem, verapamil, and quinidine in patients with chronic atrial fibrillation //J. Clinic Pharmacol. 1985. — Vol.25, N3. -P.204−209.
- Olsson B. Clinical experiebce with Ximelagatran //Abstracts XlVth World congress of cardiology, Satellite symposium «Oral direct thrombin inhibition.
- Anticoagulation strategies in the management of cardiac disorders», Sydney, Australia, May 2002.
- Oltorna L., Broccolino M., Merlini P.A. et al. Activation of the hemostatic mechanism after pharmacologic cardioversion of acute nonvalvulal atrial fibrillation //Circulation 1997. — Vol.95. — P.2003−2006.
- Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group //New Engl. J. Med. 1995. — Vol.333. — P.5−10.
- Overall quality indicators in health care and medical services /National Board of Health and Welfare. Stockholm: Socialstyrelsen, 2001. — 16 p.
- Packer D.L. Intermittent atrial fibrillation and stroke //Rev. Cardiovasc. Med.2000. -Vol.1. -P.18−19.
- Padeletti L., Pieragoli P., Colella A. et al. Prevention of paroxysmal atrial fibrillation by permanent septal atrial pacing: long-term follow up //Europ Heart J. —2001. Vol.3, Suppl.P. — P. P2-P6.
- Page R.L. Atrial fibrillation takes the spotlight in the Arrhythmia sessions at this year’s AHA //Annual Scientific Sessions of the American Heart Association november, 2000, New Orleans, USA.
- Page R.L., Wilkinson W.E., Clair W.K. et al. Asymptomaic arrhythmias in patients with symptomaic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia //Circulation. 1994. — Vol.89. — P.224−227.
- Palareti G., Leali N., Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISOCAT) //Lancet. 1996. — Vol.348. -P.423−428.
- Palazzuoli A., Ricci D., Lenzi C. et al. Transesophageal echocardiography for identifying potential cardiac soyrse in patients with stroke //Neurol. Sei. 2000. -Vol.21. -P.195−202.
- Palinkas A., Antonelli E., Picano E. et al. Clinical value of left atrial appendage flow velocity for predicting of cardioversion success in patients with non-valvular atrial fibrillation //Eur. Heart J. 2001. — Vol.22. — P.2201−2208.
- Pappone C., Augello G., Vicedomini G. et al. High efficacy combined circumferential pulmonary vein ablation, amiodarone and ibesartan for permanent atrial fibrillation // Eur. Heart J. 2003. — Vol.24. — P.726.
- Pathways of care /Ed.by S. Johnson. Oxford: Blackwall Sei., 1997. — 271 p.
- Pearce L.A., Hart R., Halperin JL. et al. Assessment of three stratifying stroke risk in patients with nonvalur atrial fibrillation //Amer. J. Med. 2000. — Vol.109, N1. — P.45−51.
- Pearson S.D., Kleefield S.F., Soukop J., et al. Critical pathways intervention to reduce length of hospital stay //Amer. J. Med. 2001. — Vol.110. — P. 175−180.
- Peck P. NASPE: Dronedarone Effective fof Atrial Fibrillation //www.pslgroup.com/dg/21550E.htm.
- Pedersen O.D. Dofetilide in the treatment of atrial fibrillation in patients with impaired ventricular function //The DIAMOND Study group, Vienna, Aug.1998. Abstr. 2037.
- Pengo V., Zasso A., Barbero F. et al. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation //Amer. J. Cardiol. 1998. — Vol.82. — P.433−437.
- Perez C. The next frontier in clinical pathways. The journey to outcomes management //Nurs Case Manag. 1996. — Vol.1, N2. — P.75−78.
- Peters K., Kienzle M. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: Complete recovery after restoration of sinus rhythm //Amer. J. Med. -1988. Vol.85. — P.242−244.
- Petersen P., Boysen G., Godtfresen J. et al. Placebo- controlled randomized trial of warfarin and aspirin for prevention of thromboembolic complication in chronic atrial fibrillation: the Copenhagen AFSAK study //Lancet. 1989. — Vol.1. — P.175−179.
- Philbin E.F., Rocco T.A., Lindenmuth N.W. et al. The results of a randomized trial of quality improvement intervention in the care of patients with heart failure. The MISCHF Study Investigators //Amer. J. Med. 2000. — Vol.109. — P.443−449.
- Phillips D.P., Christenfeld N., Glynn L.M. Increase in U.S. Medication Error Death Between 1983 and 1993 //Lancet. — 1998. — Vol.351. -P.643−644.
- Planning, implementing, and evaluating critical pathways /P.C.Dykes, K. Wheeler, eds. New York etc.: Springer, 1997. — 163 p.
- Pitzalis M., Grimaldi M., Luzzi G. et al. Handgrip enhances the efficacy of ibutilide in restoring sinus rhythm in patients with persistent atrial fibrillation //Europ. Heart. J. 2000. — Vol.21. — P.47I.
- Prystowsky E.N. Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden death //Amer. J. Cardiol. 1996. -Vol.78, N8A. — P.35−41.
- Rammanna H., Hauer R.N.W., Wittkampf F.H.M. et al. Identification of the substrate of atrial vulnerability in patients with idiopathic atrial fibrillation //Circulation. -2000.-Vol.101.-P.995−1001.
- Ranjan A., Tarigopula L., Srivastava R. et al. Effectiveness of the clinical pathway in the management of congestive heart failure //South. Med. J. 2003. — Vol.96. — P.661−663.
- Rasmussen K., Andersen A., Abrahamsen A. et al. Flecainide versus disopyramide in maintaining sinus rhythm following of chronic atrial fibrillation //Eur. Heart J. 1988. -V.9, Suppl. I.-P.52.
- Rauh R., Fischereder M., Spengel F. Transesophageal echocardiography in patients with focal cerebral ischemia of unknown cause //Stroke. 1996. — Vol.27. -P.691−694.
- Reerink I.H., Sauerborn R. Quality of primary health care in developing countries: recent experiences and future directions //J. Qual. Health Care. 1996. — Vol.8. — P. 131 139.
- Reiffei J.A. Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision //Amer. J. Cardiol. 1998. — Vol.82. -P.72N-81N.
- Reiffei J.A., Camm A.J., Haffajee C.I. et al. International consensus roundtable on atrial fibrillation //Cardiology Review. 2000. — Vol.17, N2, Suppl. — P. 1−20.
- Reimold S.C. Avoiding drug problems. The safety of drugs for supraventricular tachycardia //Eur. Heart J. 1997. — Vol.18, Suppl. C. — P. C40-C44.
- Reimold S., Cantillon C., Friedman P., Antman E. Propafenone versus Sotalol for suppression of recurrent symptomatic atrial fibrillation //Amer. J. Cardiol. 1993. -Vol.71. -P.558−563.
- Reithmann C., Dorwarth U., Dugas M. et al. Risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy for antiarrhythmic drug-induced atrial flutter //Eur. Heart J. 2003. — V.24. — 1264−1272.
- Ricard P., Levy S., Trigano J. et al. Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation //Amer. J. Cardiol. 1997. — Vol.79. -P.815−816.
- Ricard P., Yaici K., Rinaldi J. et al. Cardioversion of atrial fibrillation: how and when //Eur. Heart J. 2003. — Vol.5, Suppl. H. — P. H40-H44.
- Rajendra H.M., Dabbous O.H., Granger C.B. et al. Comparison of outcomes of patients with acute coronary syndrome with and without atrial fibrillation //Amer. J. Cardiol. 2003. — Vol.92. — P.1031−1036.
- Roy D., Talajic M., Dorian P. et al. Amiodarone to prevent recurrences of atrial fibrillation.// New Engl. J. Med. 2000. — Vol.342. — P.913−920.
- Roijer A., Eskilsson J., Olsson B. Transesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion //Eur. Heart J. 2000. — Vol.21, N10. — P.837−847.
- Rooney A., van Ostenberg P.R. Licensure, accreditation, and certification: Approaches to health services quality //Quality Assurance Project. 1999. — www. urc-chs.com.
- Ross G., Johnson D., Kobernick M. Evaluation of a critical pathway for stroke //J. Amer. Osteopath. Assoc. 1997. — Vol.97. — P.275−276.
- Ruigomez A., Johansson S., Wallander MA. et al. The incidence of chronic atrial fibrillation in general practice and its treatment pattern //J. Clin. Epidemiol. 2002. -Vol.55.-P.358−363.
- Ruigomez A., Johansson S., Wallander M.A., Garcia Rodrigues L.A. Risk of mortality in a cohort of patients newly diagnosed chronic atrial fibrillation //www.biomedcentral.com/1471−2261/2/5.
- Sackett D., Haynes B., Guyatt G., Tugwell P. Clinical epidemiology: A basic science for clinical medicine. Boston (Mass.): Little Brown, 1991.
- Sager P.T. Atrial fibrillation: Antiarrhythmic therapy versus rate control with antithrombotic therapy. Amer. J. Cardiol. — 1997. — Vol.80, N8A. — P.74G-81G.
- Saksena S., Prakash A., Krol R. et al. Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing //J. Amer. Coll. Cardiol. 1996. — Vol.28, N3. -P.687−694.
- Sanofi-Syntelabo. Halts clinical trial of arrhythmia drug after several die //www.injuryboard.com/.
- Sawin C.T., Geller A., Wolf P.A. et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons //New Engl. J.Med. 1994. — Vol.331. -P.1249−1252.
- Schmidt C., Alt E., Plewan A. et al. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation //J. Amer.Coll. Cardiol. — 1996. Vol.28, N4. — P.994−999.
- Siotia A., Muthusamy R. Neurogenic atrial fibrillation // Brit. J. Cardiol. 2004. -Vol.11,N2.-P.156−157.
- Silvet H., Young-Xu Y., Walleigh D., Ravid S. Brain natriuretic peptide is elevation in outpatients with atrial fibrillation //Amer. J. Cardiol. 2003. — Vol.92. -P.l 124−1127.
- Segal J. Anticoagulants versus antiplatelet drugs for preventing thromboembolism in atrial fibrillation (Protocol for a Cochrane review) //Cochrane Library. 2000. — Iss.3.
- Segal J.B., McNamara R.L., Miller M.R. et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter //Cochrane Library. 2001. -Iss.l.
- Segal J.B., McNamara R.L., Miller M.R. et al. The evidence regarding the drug used for ventricular rate control //J. Fam. Pract. 2000. — Vol.49, N1. — P.47−59.
- Seidl K., Zahn R., Bergmeier C. et al. Value of transesophageal echocardiography to assess the embolic risk in patients with atrial fibrillation undergoing electrical cardioversion //JACC. 2000. — Vol.35. — Iss.2, Suppl.A. -P.102.
- Seto T., Taira D., Tvesat J. et al. Cost effectivness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with Atrial Fibrillation //JACC. 1997. — Vol.29. -Nl. — P.122−130.
- Shaw C. Accreditation and ISO: International convergence on health care standards. ISQua position paper, Oct. 1996 //Int. J. Qual. Health Care. 1997. — Vol.9, N1.-P.11−13.
- Shen X., Li H., Rovang K. et al. Transesophageal echocardiography before cardioversion of recurrent atrial fibrillation: does absenct of previous atrial thrombi preclude the need of a repeat test? //Amer. Heart J. 2003. — Vol.146, N4. — P.741−745.
- Shimizu A., Yoshiga Y., Yamagata Y. et al. Determination of atrial refractory period during atrial fibrillation //Pacing Clin. Electrophysiol. 2003. — Vol.26. — P. 139S.
- Shirayama T. Imai H., Shiraishi H. et all. Effects of class I antiarrhythmic drugs against the atrial electrical remodelling //Europ. Heart J. 2000. — Vol.21. — P.326.
- Shoemaker W.C. Critical Path Medicine.//Crit. Care Med. 1974. — Vol.2, N5. -P.279.
- Silverman D.I., Manning WJ. Strategies for cardioversion of atrial fibrillation -time for a change? //New Engl. J. Med. 2001. — Vol.344, N19. — P. 1468−1469.
- Singer D. Anticoagulation: For whom and how long? //Abstracts of the 73rd Scientific Sessions of the AHA, 12−15 Nov., 2000, New Orleans, USA.
- Singh B.N. Atrial fibrillation: epidemiologic consideration and rationale for conversion and maintenance of sinus rhythm. // J. Cardiovasc. Pharmacol. Ther. 2003. -Vol.8, suppl.S. — P. 13−26.
- Sodermark T., Edhag O., Sjogren A. et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm //Br. Heart J. 1975. — Vol.37. — P.486−492.
- Sommer C., Roche B. From quality assurance to continuous quality improvement in the American health care system. Personal experiences gained through a 3-week educational stay //Swiss Surg. 1995. — Vol.1. — P.61−66.
- Spath P.L. Beyond clinical paths: Advanced tools for outcomes management. -San Francisco etc.: Jossey-Bass, 1997. 296 p.
- Stafford R.S., Singer D.E. Recent national patterns of warfarin use in atrial fibrillation //Circulation. 1998. — Vol.97. -P.1231−1233.
- State of Health Care Quality. Final report, ch. 1 //www.hcqualitycommission.gov.
- Stead L., Arthur C., Cleary A. Do multidisciplinary pathways of care affect patient satisfaction? //Health Care Risk Report. 1995. — P.13−15.
- Stellbrink C., Hanrath P. The optimal management of cardioversion of atrial fibrillation or flutterrstill a «stunning» problem //Eur. Heart J. 2000. — Vol.21. — P.795−798.
- Stewart S., Maclntyre K., MacLeod M.M. et al. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986−1996 //Eur. Heart J. 2001. — Vol.22. — P.693−701.
- Stilli D., Aimi B., Sgoifo A. et al. Dependence of temporal variability of ventricular recovery on myocardial fibrosis: role of mechanoelectric feedback? //Cardiovasc. Res. 1998. — Vol.37. -P.58−65.
- Stoddard MF. Risk of thromboembolism in acute atrial fibrillation or atrial flutter //Echocardiography. 2000. — Vol.17, N.4. — P.393−405.
- Stoddard M.F., Dawkins P.R., Prince C.R., Longaker R.A. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation //Amer. Heart J. 1995. — Vol.129. — P.1204−1215.
- Stoddard M.F., Singh P., Dawn B., Longaker R.A. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation / Amer. Heart J. 2003. -Vol.145.-P.676−682.
- Stoobandt R., Stiels B., Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation //Amer. J. Cardiol. 1997. — Vol.79. — P.418−423.
- Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study //Lancet. 1994. — Vol.343. — P.689−691.
- Stroke prevention in atrial fibrillation study: final results //Circulation. 1991. — Vol.84. — P.527−539.
- Sublow M., Thomson R., Thwaites B. et al. Anticoagulants are undsrused in the treatment of atrial fibrillation and flutter //Lancet. 1998. — Vol.352. — P. l 167−1171.
- Summers D., Soper P.A. Implementation and evaluation of stroke clinical pathways and impact on cost of stroke care //J. Cardiovasc. Nurs. 1998. — Vol.13, N1. -P.69−87.
- Sutton P.R., Yeh J.Y. Management of Atrial fibrillation. Case study and commentary //J. Clin. Outcomes Manage. 2002. — Vol.9, N11.- P.631−647.
- Suttop M.J., Kingma J.H., Jessurun E.R. The value of class Ic antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm //J. Amer. Coll. Cardiol. 1990. — Vol.16. -P.1722−1727.
- Suttop M.J., Kingma J.H., Lie-A-Huen L. et al. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm //Amer. J. Cardiol. 1989. -Vol.63. — P.693−696.
- Szekely P., Sideris D., Batson G. Maintense of sinus rhythm after atrial defibrillation //Br. Heart J. 1970. — Vol.32. — P.741−746.
- Taylor F., Cohen H., Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation //BMJ. 2001. -Vol.322.-P.321−326.
- Thamilarasan M., Klein A.L. Transesophageal echocardiography (TEE) in atrial fibrillation //Cardiology Clinics. 2000. -Vol.18, N4. — P. l-18.
- Thibault B., Talajic M., Dubuc M. et al. Thromboembolic events occur in patients with atrial fibrillation despite maintenance of sinus rhythm or use of anticoagulations //Circulation. 2000. — Vol.102. — P.627. — Abstr. 3250.
- Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. The Clinical Quality Improvement Network (CQIN) Investigators //Can. J. Cardiol.1998. Vol. 14, N5. — P.695−702.
- Tieleman R., DeLangen D., Van Gelder I.C. et al. Verapamil reduces tachycardia induced electrical remodeling of the atria //Circulation 1997. — Vol.95. — P.1945−1953.
- Tieleman R., Gosselink A., Crijns H. et al. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone // Amer. J. Cardiol. -1997.- Vol.79 -P.53−57.
- Tieleman R.G., Van Gelder I.C., Crijns H.J. et al. Early recurrences of atrial fibrillation after electrical cardioversion result of fibrillation-induced electrical remodeling of the atria? //JACC. 1998. — Vol.31 — P. 167−173.
- Tierney W.M., Overhage J.M., Takesue B.Y. et al. Using computerized guidelines to improve care //J. of Amer. Informatics Assoc. 1998. — Vol.2, N5. -P.316−322.
- Timmermans C., Lau C.P., Tse N.F. et al. Early clinical experience with the metrix autqmatic implantable atrial defibrillator //Eur. Heart J. 1997. — Vol.18, Suppl.134. — Abstr. 892.
- Tools for performance measurement in health care: A quick reference guide. -Oakbrook Terrace: Joint Commission on Accreditation of Healthcare Organizations, 2002.-105 p.
- Touboul P., Aliot E., Brembilla-Perrot B. Flecainide in the prevention of atrial fibrillation after DC conversion: comparison with quinidine //Circulation. 1991. -Vol.84, Suppl.II.-P.127.
- Touboul P., Brugada J., Capucci A., Crijins HJ. et al. Dronedarone for prevention of atrial fibrillation: A dose-ranging study //Eur. Heart J. 2003. — Vol.24, N16. -P.1481−1487.
- Tracy C.M., Aktar M., DIMarco J.P. et al. ACC/AHA Clinical competence statement on invasive electrophysiology studies, catheter ablation, and cardioversion //JACC. 2000. — Vol.36. — P.1725−1736.
- Tsai L.M., Chen J.H., Lin L.J., Teng J.K. Natural history of left atrial spontaneous echo contrast in nonrheumatic atrial fibrillation //Amer. J. Cardiol. 1997. — Vol.80. -P.897−900.
- Uto Y- Muranaga F- Kumamoto I. Creating clinical path based on analysis using hospital information system //Jpn. Hosp. 1998. — Vol.17. — P.37−43.
- Validation of long-term and post-acute care quality indicators /Abt Associates Inc. etc. CMS Contact No:500−95−0062/T.0.4,2002. — 8 p.
- Van Gelder I.C., Brundel B.J., Henning R.H. Alterations in gene expression of proteins involved in the calcium handing in patients with atrial fibrillation //J. Cardiovasc. Electrophysiol. 1999. — Vol.10. — P.522−560.
- Van Gelder I.C., Hagens V.E., Bosker H.A. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation //New Engl. J. Med. 2002. — Vol.347, N23. — P. 1834−1840.
- Van Wagoner D.R., Nerbonne J.M. Molecular basis of electrical remodeling in atrial fibrillation //J. Mol. Cell. Cardiol. 2000. — Vol.32. — P. l 101−1117.
- Villani G., Piepoli M., Villani P., Capucci A. Anticoagulation in atrial fibrillation: what is certain and what is to come //Eur. Heart J. 2003. — Vol.5, Suppl. H. — P. H45-H50.
- Vitolo E., Tronci M., Larovere M. et al. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation //Acta Cardiol. 1981. — Vol.36. — P.431−444.
- Voller H., Dovifat C., Glatz J. Home management of anticoagulation //Eur. Herat J. -2001. Vol.3, Suppl. Q. -P.Q44-Q49.
- Von der Recke G, Schmidt H, Illien S. et al. Use of transesophageal echocardiography for excluding left atrial appendage thrombi in patients wrth atrial fibrillation before cardioversion //J. Amer. Societ. Echocardiol. 2002. — Vol.15. -P.1256−1261.
- Wattigney W.A., Mensah G.A., Croft J.B. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999 // Circulation. 2003. -Vol.108-P.711−716.
- Waldo A. Measures of drug efficacy in treating atrial fibrillation //Amer. J. Cardiol. 1998. — Vol.82. — P.7I-8I.
- Wall D.K., Proyect M.M. Clinical pathway implementation guide: a methodology of managing critical pathways. Chicago: Precept Press, 1997. — 116 p.
- Walldal E., Anund I., Furaker C. Quality of care and development of critical pathway //J. of Nursing Manag. 2002. — Vol.10. — P. 115−122.
- Weed L.L. Medical records, medical education and patient care: The problem oriented record as a basic tool. Chicago: Year Book Medical Publ., 1969.
- Weigner M.J., Caulfield T.A., Danias P.G. et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours //Ann. Intern. Med. 1997. — Vol.126. — P.615−620.
- Weigner M.J., Thomas L.R., Patel U. et al. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: shot-term safety and impact on maintenance of sinus rhythm at 1 year //Amer. J. Med. 2001. — Vol.110. — P.694−702.
- Weiland D.E. Why use clinical pathways rather than practice guidelines? //Amer. J. Surg. 1997. — Vol.174. — P.592−595.
- Weinberg D.M., Mancini G.B. Anticoagulation for cardioversion of atrial fibrillation //Amer. J. Cardiol. 1989. — Vol.63 — P.745−746.
- Weingarten S. Practice guidelines and clinical pathways //Hospital Medicine /Ed. by Wachter R. et al. Philadelphia: Lippincott Williams & Wilkins, 2000. — P.39−43.
- Weingarten S., Agocs L., Tankel N. et al. Reducing lengths of stay for patients hospitalized with chest pain using medical practice guidelines and opinion leaders //Amer. J. Cardiol. 1993. — Vol.71. -P.259−262.
- Wellens H.J.J., Lau C.P., Luderitz B. et al. Atriverter: an implantable device for the treatment of atrial fibrillation//Circulation. 1998. — Vol.98. -P.1651−1656.
- Wentworth D.A., Atkinson R.P. Implementation of an acute stroke program decreases hospitalozation costs and length of stay //Stroke. 1996. — Vol.27. — P. 10 401 043.
- Weerasooriya R., Davis M., Powell A. et al. The Australian intervention randomized control of rate in atrial fibrillation trial (AIRCRAFT) //J. Amer. Coll. Cardiol. -2003. Vol.41. — P. 1697−1702.
- White R., McBurnie M., Manolio T. Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort //Amer. J. Med. 1999. -Vol.106.-P.165−171.
- Wijffels M., Kirehoff C., Dorland R. et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats //Circulation. 1995. -Vol.92.-P. 1954−1968.
- Wodlinger A., Pieper J. Low-molecular-weight heparin in transesophageal echocardiography-guided cardioversion of atrial fibrillation //Pharmotherapy. 2003. -Vol.23, N1.-P.57−63.
- Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: The Framingham study //Stroke. 1991. — Vol.22. — P.983−988.
- Wolf P.A., Mitchell J.B., Baker C.S. et al. Impact of atrial fibrillation on mortality, stroke, and medical costs //Arch. Intern. Med. 1998. — Vol.158, N3. -P.229−234.
- Wolff L. Familial auricular fibrillation //N. Engl. J. Med. 1943. — Vol.229. -P.396−398.
- Wolpert C., Haase K., Suselbeck T., Borggrefe M. Hybrid therapy for atrial fibrillation //Eur. Heart J. 2003. — Vol.5, Suppl. H. — P. H51 -H55.
- Wood M.A., Brown-Mahoney C., Kay G.N., Ellenbogen K.A. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A meta-analysis //Circulation. -2000.-Vol.101.-P.l 138−1144.
- World Health Statistics Annual, World Health Organization, Geneva //WHO Internet homepage.
- Yamada H., Kim Y., Tabata T. et al. Correlation of left atrial mechanical and electrical remodeling following short duration atrial fibrillation //J. Amer. Coll. Cardiol. -2002.-Vol.39.-P.376A.
- Yu W.C., Chen S.A., Lee S.H. et al. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiaarrhythmic drugs //Circulation. -1998. V.97. — P.2331−2337.
- Yu W.C., Hsu T.L., Tai C.T. et al. Acquired pulmonary vien stenosis after radiofrequence catheter ablation of paroxysmal atrial fibrillation //J. Cardiovasc. Electrophysiol. 2001. — Vol.12. -P.887−892.
- Yu W.C., Lee S.H., Tai C.T. et al. Reversal of atrial electrical remodeling following cardioversion of long-standing atrial fibrillation in man //Cardiovasc. Res. -1999.-Vol.42.-P.470−476.
- Zaim S., Saksena S. Peering through the looking glass: electrical therapy for atrial fibrillation in 2004 where do we stand? //J. Cardiovasc. Electrophysiol. — 2004. -Vol.15.-P.496−500.
- Zander K. Historical development of outcome-based care delivery //Crit. Care Nursing Clin. Noth Amer. 1998. — Vol.10, N1. — P. 1−11.
- Zander K. Managing outcomes through collaborative care. The application of care mapping and case management. Chicago: Amer. Hospital Publ., 1995. — 220 p. .
- Zanini R., Facchinetti A., Gall G. et al. Morbility and mortality of patients with sinus node disease: comparative effects of atrial and ventricular pacing //PACE. 1990. -Vol.12, Pt.2.-P.2076−2079.
- Zehender M., Hohnloser S., Muller B. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: Results of a comparative study and a 2 year follow-up//J Amer. Coll. Cardiol.- 1992.-Vol.19. P.1054−1059.
- Zipes D.P. Presidents page: Guidelines: Tools for building better patient care //J. Amer. Coll. Cardiol. 2001. — Vol.38, N7. — P.2089−2090.